Inflammatory Bowel Disease (IBD) Therapeutics Market
Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Share & Trends Analysis by Disease Type (Ulcerative Colitis and Crohn’s Disease), By Therapeutic Class (Biologics, Small Molecules, 5?Aminosalicylic Acid (5?ASA) / Aminosalicylates, Corticosteroids, Immunomodulators, and Others), Forecast Period (2026-2035)
Industry Overview
Inflammatory bowel disease (IBD) therapeutics market was valued at $27.4 billion in 2025 and is projected to reach $47.6 billion by 2035, growing at a CAGR of 5.8% during the forecast Period (2026-2035). The market growth is driven by rising disease prevalence, advancements in therapeutics like biologics, and increased healthcare investment. Its key factors include the growing prevalence of diseases like Crohn's and ulcerative colitis, the approval of new drug classes such as TNF inhibitors, and expanding healthcare infrastructure in emerging markets.
Market Dynamics
Rising Global Prevalence and Earlier Diagnosis
The growing incidence and prevalence of Crohn’s disease and ulcerative colitis, particularly in North America, Western Europe, and rapidly urbanizing regions of Asia-Pacific, remains one of the strongest demand-side drivers for the IBD therapeutics market. Improved access to gastroenterology services, greater awareness of gastrointestinal symptoms, and advancements in colonoscopy, biomarker testing, and radiologic imaging are contributing to earlier diagnosis. This expands the treatable patient pool and increases long-term therapeutic needs, as IBD is a chronic, lifelong condition requiring continuous medical intervention. As emerging economies improve healthcare infrastructure, diagnosed cases are rising sharply, further boosting global demand for biologics and advanced oral therapies.
Expansion of the Therapeutic Pipeline and New Drug Approvals
Robust R&D activity, characterized by novel biologics, next-generation IL-23 inhibitors, anti-TL1A therapies, S1P receptor modulators, and JAK inhibitors, is accelerating innovation in the IBD therapeutics landscape. Pharmaceutical companies are heavily investing in mechanism-specific drugs that offer improved efficacy, convenience, and safety compared to earlier anti-TNF therapies. Continuous approvals of new agents and expanded indications, such as the growing adoption of oral small-molecule treatments, are reshaping therapeutic algorithms and increasing the overall market value. This influx of innovative therapies enhances patient options, supports premium pricing, and strengthens competition, collectively driving sustained revenue growth.
Shift Toward Biologics, Biosimilars, and Personalized Treatment Approaches
Another major driver is the increasing uptake of biologics, including anti-TNFs, anti-integrins, and IL-23 inhibitors, which continue to dominate treatment for moderate-to-severe IBD. Meanwhile, biosimilars are expanding accessibility in cost-sensitive markets by reducing therapy costs and driving the adoption of biologic treatment earlier in the disease course. Additionally, the transition toward personalized medicine supported by therapeutic drug monitoring (TDM), biomarker-guided treatment selection, and precision dosing enhances clinical outcomes and increases overall treatment adoption. As health systems and clinicians increasingly prioritize tailored regimens to improve remission rates, demand for advanced, targeted therapies continues to rise, reinforcing long-term market expansion.
Market Segmentation
- Based on the disease type, the market is segmented into ulcerative colitis and crohn’s disease.
- Based on the Therapeutic Class, the market is segmented into biologics, small molecules, 5?aminosalicylic acid (5?ASA) / aminosalicylates, corticosteroids, immunomodulators, and others.
Biologics Segment to Grow at a Considerable Market Share
Biologics stand out as the largest and fastest-growing segment driving the global inflammatory bowel disease (IBD) therapeutics market. Biologics dominate due to their superior efficacy in inducing and maintaining remission in both ulcerative colitis and crohn’s disease, especially in moderate-to-severe cases where conventional therapies show limited response. The rising adoption of advanced biologics, including anti-TNF agents, anti-integrins, and IL-12/23 inhibitors, alongside the rapid uptake of biosimilars that improve affordability and access, has significantly expanded patient usage globally. Additionally, the growing prevalence of IBD, increasing treatment awareness, and strong clinical support for biologics long-term benefits further reinforce this segment’s leadership in market revenue and future growth trajectory.
Crohn’s Disease: A Key Segment in Market Growth
Crohn’s Disease represents the key segment driving growth within the global inflammatory bowel disease (IBD) therapeutics market, owing to its rising prevalence, complex disease progression, and increasing need for advanced biologic and targeted therapies. Unlike ulcerative colitis, which is largely confined to the colon, Crohn’s Disease can affect any part of the gastrointestinal tract and often involves deeper tissue layers, leading to more severe complications such as strictures, fistulas, malnutrition, and repeated surgeries. This complexity significantly increases the demand for high-value therapeutics, including anti-TNF agents, anti-integrins, IL-23 inhibitors, small-molecule JAK inhibitors, and newly emerging S1P receptor modulators. Growing adoption of personalized medicine, increasing biomarker-based treatment selection, and expansion of biosimilars further accelerate segmental growth. Additionally, the global rise in smoking rates among young adults westernized diets, and improved diagnostic capabilities continue to expand the patient pool. Pharmaceutical companies are heavily investing in pipeline innovations specifically targeting Crohn’s Disease due to higher relapse rates and lower remission levels compared to ulcerative colitis. As a result, Crohn’s Disease accounts for a larger share of therapeutic spending and is expected to remain the fastest-growing disease type segment throughout the forecast period.
Regional Outlook
the global inflammatory bowel disease (ibd) therapeutics market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region to Hold a Substantial Growth Rate
In North America, the US dominates the global inflammatory bowel disease (IBD) therapeutics market, holding the largest market share due to its advanced healthcare infrastructure, high disease prevalence, and strong adoption of innovative therapies. The country has one of the highest diagnosed rates of Crohn’s disease and ulcerative colitis worldwide, supported by robust clinical awareness, frequent screening, and widespread access to gastroenterology specialists. This significantly expands the treatable patient pool and drives continuous demand for biologics, targeted therapies, and newly approved small-molecule drugs. Additionally, the US leads in rapid uptake of premium-priced biologics such as anti-TNF, anti-IL-23, and anti-integrin therapies owing to favorable reimbursement frameworks and strong insurance coverage for specialty drugs. The market is further strengthened by the presence of major pharmaceutical companies headquartered or heavily active in the U.S., including AbbVie, Janssen, Bristol Myers Squibb, Pfizer, and Eli Lilly, all of which continuously invest in IBD R&D and launch next-generation therapies in the US market first. Extensive clinical trial activity, advanced regulatory pathways, and a strong culture of innovation ensure faster commercialization of novel mechanisms like TL1A inhibitors and S1P modulators. Together, these factors position the United States as the undisputed leader in the global IBD therapeutics market.
Market Players Outlook
The major companies operating in the global inflammatory bowel disease (IBD) therapeutics market include AbbVie Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.
Recent Development
- In September 2025, Johnson & Johnson has been actively involved in the development of treatments for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, affecting up to 10 million people globally. While there is currently no cure for IBD, the company recently received FDA approval for a new medication that contributes to its long history of treatment innovations. Diagnosing IBD is complex, often requiring multiple tests, as symptoms like diarrhea and abdominal pain can be confused with other conditions. Despite these challenges, Johnson & Johnson remains dedicated to researching therapies that suppress the immune response and reduce inflammation, having introduced the first biologic treatment for IBD in the 1990s and continuing to enhance patient care through ongoing development.
- In 2025, NICE approved guselkumab (Tremfya) for use in the NHS to treat moderate to severe ulcerative colitis and moderately to severely active Crohn’s disease in patients unresponsive to other treatments or suffering from severe side effects.
- In December 2024, Biosimilars for inflammatory bowel disease (IBD) are poised for expansion in early 2025, potentially improving care access and reducing healthcare costs. Recent FDA approvals include a sixth biosimilar for Stelara (ustekinumab) and a third interchangeable biosimilar for Humira (adalimumab), in addition to a citrate-free formulation of Cyltezo (adalimumab-adbm) for IBD and other inflammatory conditions.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global inflammatory bowel disease (IBD) therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis – Disease Type | Therapeutic Class ($ Million)
- Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Inflammatory Bowel Disease (IBD) Therapeutics Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Inflammatory Bowel Disease (IBD) Therapeutics Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Inflammatory Bowel Disease (IBD) Therapeutics Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Inflammatory Bowel Disease (IBD) Therapeutics Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Inflammatory Bowel Disease (IBD) Therapeutics Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Inflammatory Bowel Disease (IBD) Therapeutics Market Revenue and Share by Manufacturers
- Inflammatory Bowel Disease (IBD) Therapeutics Diagnostic Technique Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Takeda Pharmaceutical Co. Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Diagnostic Technique Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis by Disease Type ($ Million)
- Ulcerative Colitis
- Crohn’s Disease
- Global Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis by Therapeutic Class ($ Million)
- Biologics
- Small Molecules
- 5?Aminosalicylic Acid (5?ASA) / Aminosalicylates
- Corticosteroids
- Immunomodulators
- Others
- Regional Analysis
- North American Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis – Disease Type | Therapeutic Class | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis – Disease Type | Therapeutic Class | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis – Disease Type | Therapeutic Class | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Inflammatory Bowel Disease (IBD) Therapeutics Market Sales Analysis – Disease Type | Therapeutic Class | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Allergan plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategie
- AstraZeneca Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bausch Health Companies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol Myers Squibb (BMS)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Celltrion Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ferring Pharmaceuticals
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gilead Sciences, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GSK plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson Services, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Roche Holding AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Co. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
2. Global Ulcerative Colitis Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
3. Global Crohn’s Disease Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
4. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
5. Global Biologics Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
6. Global Small Molecules Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
7. Global 5?Aminosalicylic Acid (5?ASA) / Aminosalicylates Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
8. Global Corticosteroids Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
9. Global Immunomodulators Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
10. Global Other Therapeutic Class Inflammatory Bowel Disease (IBD) Therapeutics Market Research And Analysis By Region, 2025–2035 ($ Million)
11. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
13. North American Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
14. European Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
15. European Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
16. Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Disease Type, 2025–2035 ($ Million)
17. Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
18. Rest of the World Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Region, 2025–2035 ($ Million)
19. Rest of the World Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Diagnostic Technique, 2025–2035 ($ Million)
20. Rest of the World Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Analysis by Therapeutic Class, 2025–2035 ($ Million)
1. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Disease Type, 2025 Vs 2035 (%)
2. Global Ulcerative Colitis Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
3. Global Crohn’s Disease Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
4. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Therapeutic Class, 2025 Vs 2035 (%)
5. Global Biologics Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
6. Global Small Molecules Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
7. Global 5?Aminosalicylic Acid (5?ASA) / Aminosalicylates Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
8. Global Corticosteroids Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
9. Global Immunomodulators Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
10. Global Other Therapeutic Class Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
11. Global Inflammatory Bowel Disease (IBD) Therapeutics Market Share By Region, 2025 Vs 2035 (%)
12. US Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
13. Canada Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
14. UK Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
15. France Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
16. Germany Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
17. Italy Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
18. Spain Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
19. Russia Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
20. Rest of Europe Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
21. India Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
22. China Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
23. Japan Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
24. South Korea Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
26. ASEAN Economies Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
28. Latin America Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
29. Middle East and Africa Inflammatory Bowel Disease (IBD) Therapeutics Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Inflammatory Bowel Disease (IBD) Therapeutics Market in 2025 is estimated to be around $27.4 billion.
North America holds the largest share in the Inflammatory Bowel Disease (IBD) Therapeutics Market.
Leading players in the Inflammatory Bowel Disease (IBD) Therapeutics Market include AbbVie Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd, among others
The Inflammatory Bowel Disease (IBD) Therapeutics Market is expected to grow at a CAGR of 5.8%from 2026 to 2035.
The Inflammatory Bowel Disease (IBD) Therapeutics Market is driven by the rising prevalence of IBD, increasing patient awareness, and growing demand for advanced treatment options.
